What is the Role of Peritoneal Dialysis in Optimising ESRD Patient Outcomes?

Slides:



Advertisements
Similar presentations
AKI in Pediatrics Patrick D. Brophy MD Associate Professor
Advertisements

Acute Renal Replacement Therapy for the Infant Dr.Fahad Gadi, MD Pediatrics Demonstrator King Abdulaziz University Rabigh Medical School.
Acute Renal Replacement Therapy for the Infant Dr.Fahad Gadi, MD Pediatrics Demonstrator King Abdulaziz University Rabigh Medical School.
Hemodiafiltration and Hemofiltration
Dialysis in AMU Dr Mary Rogerson, Nephrologist, SGH.
Nuevas Soluciones en DP, Sirven? Prueba en diabéticos con transporte peritoneal alto y promedio alto Dr. José Ramón Paniagua Sierra Unidad de Investigación.
How best to control salt overload in hypertension? - Dietetic? - Aligning dialysate sodium with patient's serum sodium -Prohibition of sodium profiling.
A Workshop Facilitated by Glenda M. Payne, RN, MS, CNN ESRD Technical Advisor, CMS Regions 4 & 6 Dallas, TX.
Renal Replacement Therapy (RRT)
Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
End Stage Renal Disease in Children. End stage kidney disease occurs when the kidneys are no longer able to function at a level that is necessary for.
The PREVEND Study: Screening for micro-albuminuria
The future of haemodialysis in the UK RCP advanced medicine 2013 Cormac Breen Consultant Nephrologist Guy's and St Thomas' Hospitals London.
NON-TRADITIONAL RENAL REPLACEMENT THERAPY Hafez Bazaraa.
Treatment Options for End Stage Kidney Disease Dr Vipula De Silva.
Renal Replacement Therapy: What the PCP Needs to Know.
Measurement and preservation of residual renal function (RRF) in haemodialysis patients Elizabeth Lindley and David Keane Leeds Teaching Hospitals NHS.
ECMO in CRRT – What are the Data?
Cheaper Kidney Care Vs. Redesigning kidney services to improve patient choice, shared decision making and deliver NHS costing savings.
Elimination of Phosphate in HD and PD Reference: Kuhlmann MK. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif.
Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend.
Finnish Registry of Kidney Disease, FRKD Quality Registries Meeting Stockholm, December 8th-9th, 2014 presented by: Carola Grönhagen-Riska (chair of the.
PRINCIPLES OF DIALYSIS DR SAAD ALSHOHAIB ASSOCIATE PROFESSOR IN MEDICINE AND NEPHROLOGY KAUH.
Feast or Famine: Survival and Chronic Kidney Disease Kerin Worley and Deb Gipson UNC Chapel Hill April, 2004.
“Yes Minister, we can deliver cheaper kidney care” Lisa Burnapp Lead Nurse-Living Donation, NHS Blood & Transplant Consultant Nurse-Living Donor Kidney.
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
IRC OUTLINES 1. New Classification of CKD according to KDIGO Dec Prevalence of CKD 3. Prevalence of RRT 4. Description of Integrated Renal Care.
Approach to Advanced Kidney Disease Management in the Elderly Source: Schell JO, Germain MJ, Finkelstein FO, et al. An integrative approach to advanced.
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
RENAL DISEASE IN DIABETES
SM Gatmiri, MD, Nephrologist Imam Khomeini Hospital,
Outcome of patients started on PD as first line therapy, Saira Usama, Jamal S. Alwakeel, Ahmad H. Mitwalli, Abdulkareem Alsuwaida, Akram Askar, King Khalid.
Dr. Charu Kartik Senior Clinical Dietitian KFSH&RC,Riyadh Dr. Charu Kartik Senior Clinical Dietitian KFSH&RC,Riyadh NUTRITIONAL CO-MORBITIES POST RENAL.
Peritoneal Dialysis for Elderly Patients: A Review Source: Tesar V. Peritoneal dialysis in the elderly—is its underutilization justified? Nephrol Dial.
ANZDATA Registry Annual Report 2013 Philip Clayton CHAPTER 9 KIDNEY DONATION 2013 Annual Report - 36th Edition PERITONEAL DIALYSIS CHAPTER 6.
PERITONEAL MEMBRANE CHARACTERISTICS IN SAUDI PATIENTS Prof. Jamal Alwakeel, Dr Saira Usama Dr Abdulkareem Alsuwaida, Dr Mohammad AL Ghonaim, Dr Akram.
Peritoneal Dialysis End Stage Renal Disease Causes and Treatment Methods.
James Heaf Herlev Hospital University of Copenhagen
Renal Medicine David Johnson Princess Alexandra Hospital Brisbane, Australia A Comparison of APD vs CAPD on Patient Outcomes A Comparison of APD vs CAPD.
Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Section 5: Configuration of healthcare to manage CKD.
Dialysis: outcome and complications. Introduction Outcomes – 20%+ of dialysis patients die each year, 3YS diabetics ~50% Technical complications –PD –Haemo.
DIALYSIS Dr. Frank Edwin.
Review of literature and report of experience with erythropoietin in ESRD populations Summary to FDA Cardio Renal Committee J. Michael Lazarus, M.D. CMO.
Excessive fluid is not needed: So why is Dr. Durward so wasteful? Timothy E Bunchman MD Professor & Director Pediatric Nephrology
Chapter 5 Peritoneal Dialysis 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013 ANZDATA gratefully acknowledges the contributions of the Peritoneal.
“Adequacy in PD prescription What, How, When?
Predialysis education: some cliffhangers. Transplantation Renal Replacement Therapy Hemodialysis Peritoneal Dialysis Options for End-Stage Renal Disease.
Chronic renal failure and common accompanying diseases Hradec Králové, November 2007 © by Adrian Franke.
Acute Renal Failure Doç. Dr. Mehmet Cansev. Acute Renal Failure Acute renal failure (ARF) is the rapid breakdown of renal (kidney) function that occurs.
Progression of Chronic Kidney Disease
What happens to patients returning to dialysis after transplant failure? Data from the UK Renal Registry Dr Lynsey Webb 1, Dr Anna Casula 1, Dr Charlie.
Diabetes And Hemodialysis 1 Dr.Ruba Nashawati. 2.
Medical Technology and Practice Patterns Institute 4733 Bethesda Ave., Suite #510 Bethesda, MD Phone: Fax: Comparison of.
Long Term Peritoneal Dialysis In Children – Frequent Complications Conclusions: Peritoneal Dialysis is the method of choice for pediatric patients, with.
Preemptive Kidney Transplant (PKT) – the Optimal Therapy in ESRD Reference: Connie L. Davis. Preemptive transplantation and the transplant first initiative.
Chronic Kidney Disease (CKD) Dr. Sham Sunder. Now we know why the titanic sank !! < 0.5 % 5- 10%
World Kidney Day 2016: Kidney Disease & Children
Optimization of pre-ESRD care: The key to improved dialysis outcomes
The ADEMEX Trial Adequacy of PD in Mexico Reference
Principles of dialysis
Intensive Hemodialysis: Applied Clinical Practice
The CANUSA Trial Reference
Acute and Chronic Renal Failure
CHAPTER 5 Paediatric Renal Replacement Therapy
Andrew Durward St Thomas NHS Foundation Trust Orlando 2017 CRRT IN AKI.
A Six-hour Hemodialysis Without a Significant Increase in Dialysis Dose, as Judged by Kt/V, Can Reduce the Dosage of Erythropoietin Department of Kidney.
Meeting the challenges of the new K/DOQI guidelines
Benefits of preserving residual renal function in peritoneal dialysis
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Presentation transcript:

What is the Role of Peritoneal Dialysis in Optimising ESRD Patient Outcomes?

PD: Optimising Outcomes? Slow Progression of Renal Disease Prevent Additional Injury to Kidneys Manage Co-morbid Conditions – Cardiovascular Disease – Diabetes – Anemia Preserve Vascular Access Site Maintain Proper Nutrition Pre-dialysis Education for Patient Pre-ESRDESRD Preserve Residual Renal Function Prevent Additional Injury to Kidneys Delay Long Term Complications Manage Co-morbid Conditions – Cardiovascular Disease – Diabetes – Anemia Preserve/Maintain Vascular Access Site Maintain Proper Nutrition Patient Social and Employment Rehabilitation Blood Purification Electrolyte and Acid Base Equilibrium Goals Before and Following Initiation of Dialysis Initiation of Dialysis

PD: Optimising Outcomes? Non-Medical Factors that Impact on ESRD Modality Selection Financial/reimbursement Physician experience with both therapies Patient and family understanding of modality options Availability of resources (staff, finance, space, etc) Social factors Cultural habits Nissenson AR, Kidney Int, 1993; 43 (Suppl. 40):S120-S127

PD: Optimising Outcomes? Modality Selection and Distribution Where Do We Want To Be?

PD: Optimising Outcomes? Total survival is more important than survival on each therapy HD TX PD “What patients want to know is which sequence of RR modalities will increase their survival as long as possible & this with the best Quality of Life” Van Biesen 2000

PD: Optimising Outcomes? Integrated Care Approach “Start renal replacement therapy in ESRD patients with PD, transfer them to HD when problems with PD occur, and transplant them when the possibility exists” Lameire N, et al, Seminar of Uro-Nephrology, (1999)

PD: Optimising Outcomes? Integrated care concept: Patient survival and quality of life are two very important factors in the selection of a dialysis modality The majority of studies have compared the two modalities as « competitors » rather than as « complementary » techniques Since every RRT has a technical « drop-out », it is very likely that a patient will need several modalities during his lifetime and transfer from one technique to another will often be needed.

PD: Optimising Outcomes? Integrated Therapy - questions Does the physician believe that all RRT modalities should be made available to each patient ? Should the patient have a free choice? Does each RRT modality have a role to play during the lifetime of a patient with renal failure ?

PD: Optimising Outcomes? Reasons for Modality Switch Van Biesen WE, et al, J Am Soc Nephrol 2000;11: Access CV Poor BP Personal Peritonitis Social Adequacy Leakage of Problems Problems Control Choice Exit-Site Problems or UF Dialysis Fluid Access CV Poor BP Personal Peritonitis Social Adequacy Leakage of Problems Problems Control Choice Exit-Site Problems or UF Dialysis Fluid Haemodialysis to Peritoneal Dialysis Peritoneal Dialyisis to Haemodialysis Percent of patients 50% 25% 14% 40% 25% 12% 11% 23%

PD: Optimising Outcomes? Integrated ESRD Care Residual Renal Function Hemodialysis Creatinine Clearance (ml/min) Time on Dialysis Initiation of Dialysis Peritoneal Dialysis Transplant PD

PD: Optimising Outcomes? Challenges for PD Can PD stand on an equal footing with HD? If PD is to be used for RRT, it must give equivalent results both for mortality and morbidity as does HD

PD: Optimising Outcomes? Where is PD today? Similar survival to HD PD is treatment of choice for children Peritonitis and exit-site infection rates have been reduced Clearance targets can be achieved Lower costs than HD Good treatment prior to transplantation

PD: Optimising Outcomes? PD as the Initial Form of Renal Replacement Therapy Better initial survival Preserves residual renal function Effective blood pressure and volume control PD  Transplant: reduced risk of early acute renal failure Reduced risk of being infected by a blood borne virus Delays the use of HD blood access sites Quality of life

PD: Optimising Outcomes? Initial Survival Advantage of PD - Canadian Results Patient Survival (%) Months patients P<0.001 Fenton AJKD 30:334-42, 1997

PD: Optimising Outcomes? HD PD to HD Van Biesen JASN 2000; 11: Comparing Survival of “Integrated Care” Patients with HD Patients

PD: Optimising Outcomes? Possible Causes Better preservation of residual renal function in PD. Moist JASN 11:556-64, 2000 The ”unphysiology” of HD. Kjellstrand KI 7(S2):530-36, 1975 Lopot NDT 13(S6):74-78, 1998 Monday HD mortality increased 58% relative to other days. Bleyer KI 55:1553-9, 1999

PD: Optimising Outcomes? PD as the Initial Form of Renal Replacement Therapy Better initial survival Preserves residual renal function Effective blood pressure and volume control PD  Transplant: reduced risk of early acute renal failure Reduced risk of being infected by a blood borne virus Delays the use of HD blood access sites Quality of life

PD: Optimising Outcomes? Preservation of residual renal function Lysaght et al, ASAIO Trans, 1991; 37: Time on therapy in months Residual Creatinine Clearance (ml/min) CAPD (n=58) HD (n=57)

PD: Optimising Outcomes? Preservation of residual renal function Lang et al, PDI 21:52-57, 2001

PD: Optimising Outcomes? Risk of RRF Loss Odds Ratio Multivariate Analysis1843 patients * p<0.05 ** p<0.01 *** p<0.001 ** *** * * ** *** * Moist JASN 11: , 2000

PD: Optimising Outcomes? What are the benefits of preserving residual renal function? Reduces Mortality Contributes to total solute clearance (1 ml/min CrCl = 10 liter CrCl/week) Facilitates volume control Allows for more liberal diet and fluid intake Provides endocrine functions Erythropoietin production Ca++, phosphorus and vitamin D homeostasis Improves  2-microglobulin and middle molecule clearance Improves nutritional status Improves QoL Increases total Na removal Davies, S., 2000

PD: Optimising Outcomes? Causes of RRF Preservation in PD Avoidance of Dehydration HD: production of inflammatory mediators by blood contact McCarthy JASN 4:367, 1993 Lysaght ASAIO Trans 37: , 1991 Better clearance of middle molecules, lipophilic and proteinbound toxins.

PD: Optimising Outcomes? n=33 n=21 n=24 n= Healthy Control HD PD CRF Without dialysis Serum CRP, ng/ml Serum CRP Values Haubitz et al. PDI 16(2): , 1996 ** *# *p<0.01 vs. control #p<0.01 vs. PD

PD: Optimising Outcomes? PD as the Initial Form of Renal Replacement Therapy Better initial survival Preserves residual renal function Effective blood pressure and volume control PD Transplant: reduced risk of early acute renal failure Reduced risk of being infected by a blood borne virus Delays the use of HD blood access sites Quality of life

PD: Optimising Outcomes? Difference in BP Control by Dialysis Modality The prevalence of hypertension in HD patients is approximately 80% vs. approximately 50% in PD patients. “Hypertension is not optimally controlled in HD and PD, but is better controlled in PD than HD” “Lower blood pressure in PD patients is attributed to the more successful achievement of dry weight by slower ultrafiltration” Mailloux AJKD 1998; 32(S3), S120-S141 NKF Taskforce on CV Disease

PD: Optimising Outcomes? Effect of CAPD Blood Pressure Control Months % Variation From Baseline Saldanha AJKD 1993; 21: Patients transferred from HD to PD (n = 67) Weight Hematocrit Blood Pressure * * * * ****** * * * p<0.05

PD: Optimising Outcomes? Modality and Cardiovascular Disease Canziani MD, et al, Artificial Organs, 1995; 19:

PD: Optimising Outcomes? PD as the Initial Form of Renal Replacement Therapy Better initial survival Preserves residual renal function Effective blood pressure and volume control PD Transplant: reduced risk of early acute renal failure Reduced risk of being infected by a blood borne virus Delays the use of HD blood access sites Quality of life

PD: Optimising Outcomes? Transplantation and the role of PD Graft function immediately after transplantation is important 24% of PD patients have delayed graft function (DGF) vs. 50% of HD patients* Patients with delayed graft function have a 10% decreased graft survival Reduced need of post-transplantation dialysis PD patients have lower usage of immunosuppressive medication* PD patients suffer a lower incidence of late infections* * Perez Fontan M, Perit Dial Int, 1996, 16: 48-54

PD: Optimising Outcomes? Dialysis Modality and Delayed Graft Function GroupPDHDP Value % anuric in first 24 h <0.001 % dialysis in first week <0.001 % treated for rejection % non-functioning graft at discharge Bleyer et al. J Am Soc Nephrol 10: , 1999

PD: Optimising Outcomes? PD as the Initial Form of Renal Replacement Therapy Better initial survival Preserves residual renal function Effective blood pressure and volume control PD Transplant: reduced risk of early acute renal failure Reduced risk of being infected by a blood borne virus Delays the use of HD blood access sites Quality of life Cheaper

PD: Optimising Outcomes? Hepatitis B & C 309 patients Brazil High background prevalence of Hepatitis B & C Seroconversion partly related to blood transfusion (p=0.05) Seroconversion (%/yr) P<0.001 P<0.02 Cendoroglo Neto NDT 10:240-46, 1995

PD: Optimising Outcomes? Modality and Hepatitis C Pereira B. Kidney Int, 1997; 51:

PD: Optimising Outcomes? Why lower risk of HCV in PD? Lower requirement for blood transfusion than HD patients The absence of a vascular access site and extracorporeal blood circuit reduces the risk for parenteral exposure to the virus PD is a home therapy and it offers a more isolated environment Pereira KI 1997; 51:

PD: Optimising Outcomes? PD as the Initial Form of Renal Replacement Therapy Better initial survival Preserves residual renal function Effective blood pressure and volume control PD Transplant: reduced risk of early acute renal failure Reduced risk of being infected by a blood borne virus Delays the use of HD blood access sites Quality of life

PD: Optimising Outcomes? Total lifespan of vascular access Creation and maintenance of adequate vascular access remains a major problem in HD ESRD patients have compromised cardiovascular systems Any strategy that can augment the total lifespan of vascular access is of value Additional time is “won” by starting PD

PD: Optimising Outcomes? Modality and EPO - Japan Shinzato T, et al, Kidney Int, 1999; 5:

PD: Optimising Outcomes? Modality and EPO - Europe House AA, et al, Nephrol Dial Transplant, 1998; 13:

PD: Optimising Outcomes? Modality and Transfusions House AA, et al, Nephrol Dial Transplant, 1998; 13:

PD: Optimising Outcomes? What is the Role of PD in Optimising ESRD Patient Outcomes? Influenced by: –Availability of modality options –Profile of co-morbidities –Patient choice and self-care motivation –Physician experience and knowledge –Outcome evidence

PD: Optimising Outcomes? Following an integrated strategy of dialysis that uses PD as an initial therapy then HD may improve total patient survival and preserve societal resources which could be reallocated to treat more of the continuously increasing population of ESRD patients. Conclusion Dratwa 1999